Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

Neoptolemos, JP, Palmer, DH, Ghaneh, P et al. (31 more authors) (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet, 389 (10073). pp. 1011-1024. ISSN 0140-6736

Abstract

Metadata

Authors/Creators:
  • Neoptolemos, JP
  • Palmer, DH
  • Ghaneh, P
  • Psarelli, EE
  • Valle, JW
  • Halloran, CM
  • Faluyi, O
  • Reilly, DAO
  • Cunningham, D
  • Wadsley, J
  • Darby, S
  • Meyer, T
  • Gillmore, R
  • Anthoney, DA
  • Lind, P
  • Glimelius, B
  • Falk, S
  • Izbicki, JR
  • Middleton, GW
  • Cummins, S
  • Ross, PJ
  • Wasan, H
  • McDonald, A
  • Crosby, T
  • Ma, YT
  • Patel, K
  • Sherriff, D
  • Soomal, R
  • Borg, D
  • Sothi, S
  • Hammel, P
  • Hackert, T
  • Jackson, R
  • Büchler, MW
Copyright, Publisher and Additional Information: © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license.
Dates:
  • Published: 17 March 2017
  • Published (online): 24 January 2017
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 31 Jan 2017 15:48
Last Modified: 05 Oct 2017 16:22
Published Version: https://doi.org/10.1016/S0140-6736(16)32409-6
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/S0140-6736(16)32409-6

Share / Export

Statistics